基于Z值的检验后风险作为阳性无创产前筛查后替代阳性预测值的风险指标
无创产前筛查阳性报告自2017年起常附阳性预测值以辅助临床决策,但其计算依赖人群患病率,无法反映个体妊娠风险。本文讨论阳性预测值的局限性,并提出基于目标染色体过量程度(Z值)的检验后风险作为替代指标。
要点
- 阳性预测值基于检测灵敏度和特异度及人群患病率计算。
- 阳性预测值不能作为准确且特异的个体妊娠风险指标。
- 作者建议考虑基于Z值的检验后风险作为替代指标。
核心结论
- 阳性预测值的计算方式使其无法作为准确且特异的个体妊娠风险指标。
- 作者建议考虑基于目标染色体过量程度(Z值)的检验后风险作为替代指标。
研究设计与样本
- 本文为论述性文章,讨论无创产前筛查阳性结果报告中阳性预测值的局限性及临床意义,并提出替代指标。
主要发现
- 阳性预测值基于检测对特定疾病的灵敏度和特异度计算,并纳入母亲年龄(有时进一步调整孕周)的染色体非整倍体患病率。
- 美国主要无创产前筛查提供者普遍使用阳性预测值。
- 阳性预测值的计算方式使其无法作为准确且特异的个体妊娠风险指标。
关键数值与推荐
- 自2017年以来,阳性结果报告通常包括阳性预测值以辅助知情临床决策。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Noninvasive prenatal screening is a long-established and widely used methodology to screen pregnancies for the most common prenatal chromosomal aneuploidies. Since 2017, positive result reports have typically included a positive predictive value to assist informed clinical decision-making. Positive predictive value is calculated based on an assay's sensitivity and specificity for a particular condition, and for the purpose of noninvasive prenatal screening, the aneuploidy's prevalence by maternal age, sometimes further adjusted by gestational age, are included in the calculation. Considering the ubiquitous use of positive predictive value by major noninvasive prenatal screeningproviders in the US, it is important to consider its limitations and consequent clinical implications. Here we discuss how the calculation of positive predictive value for screen positive results precludes the ability of positive predictive value to act as a risk metric that is accurate for and specific to an individual pregnancy, and suggest posttest risk based on the amount of target chromosome excess (Z-score-based posttest risk) as an alternative metric for consideration.
引用
- Gaudet E, Persson F, Saidel M, et al. Z-score-based posttest risk as an alternative risk metric to positive predictive value following positive noninvasive prenatal screening. Am J Obstet Gynecol. 2024. PMID: 39689779. doi:10.1016/j.ajog.2024.12.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。